Industry

Industry in One Page

Sagility operates in U.S. healthcare operations outsourcing — running the administrative, clinical, and member-facing back office for U.S. health insurers, hospitals and physicians, and pharmacy benefit managers. The work is non-discretionary: claims must be adjudicated, appeals reviewed, members enrolled, providers credentialed, and bills sent every day a U.S. health plan is open. Money flows from a small group of very large payers and hospital systems down through a $48-49 billion outsourced wallet (2024) into a handful of global vendors that deliver from India, the Philippines and the Caribbean while keeping U.S.-based clinical and onshore staff. Margins exist because (a) U.S. wage arbitrage against offshore labor is wide, (b) HIPAA-grade compliance, payer/provider contracts, and 5-7 year implementation cycles make switching expensive, and (c) regulated clinical work (utilization management, payment integrity, Star ratings, risk adjustment) can only be done by trained humans. This is not generic BPO: the unit sold is a domain-trained human — coder, nurse, claims adjudicator — wrapped around a HIPAA-compliant workflow, and the customer's pain is regulatory complexity, not just cost.

Takeaway: a small set of very large U.S. payers sits at the top of a $48-49 billion outsourced wallet; vendors compete on domain depth and offshore unit cost.

How This Industry Makes Money

A healthcare BPM vendor sells one of three units: an FTE-month (a trained agent or clinician dedicated to a client), a per-transaction fee (per claim adjudicated, per call handled, per chart coded), or an increasingly common outcome-based fee tied to denials recovered, dollars saved through payment integrity, or Star-rating gates met. Revenue is recurring under 3-7 year MSAs with rolling SOWs; clients can terminate for convenience, but rarely do — Sagility's disclosed top-5 average tenure is 18 years, and industry retention runs above 95% for established vendors.

The cost stack is roughly 65-72% people (wages, benefits, training, attrition replacement), 8-12% technology and licenses, 8-12% facilities and delivery, residual SG&A. Because most agents sit in India and the Philippines, every point of INR/PHP wage inflation, every basis point of FX move, and every attrition cohort re-trained shows up in margins within two quarters.

Takeaway: the profit pool tilts away from voice/data-entry and toward clinically licensed and analytics-led work; that's where price holds and where AI displacement is slowest.

Capital intensity is modest. Tangible capex runs 2-4% of revenue; the bigger capital story is acquisitions — payment-integrity specialists, GenAI startups, and regional onshore players — which is how every public peer (EXL, Genpact, WNS, Sagility) has filled capability gaps. Bargaining power sits with the top three or four U.S. payers, who can dictate price, demand productivity give-backs, and audit vendors at will; the vendor's only counter is operational stickiness and the cost of switching a 5,000-FTE program.

Demand, Supply, and the Cycle

Demand is driven by the non-discretionary mechanics of U.S. healthcare itself. The U.S. healthcare market reached US$5.26 trillion in 2024 (~18% of GDP), and CMS projects US$6.62 trillion by 2028 (5.9% CAGR). The operations layer — the back office of payers and providers — was US$211 billion in 2024 and is projected to reach US$253-263 billion by 2028.

The cycle hits the operations layer differently than the broader system. Three drivers move the needle:

Unlike commercial banking BPO or telco contact centers — which see calls drop in a recession — healthcare ops volume is anchored to membership and claims volume, both stable to growing through downturns. That structure is why the industry trades at a premium to generic BPO and why the 2025-26 hospital cost crunch reads as a tailwind for vendors. The vulnerable end is the routine voice-and-data-entry layer, where GenAI is lowering per-transaction prices.

Competitive Structure

The industry is fragmented at scale with consolidation accelerating. No listed pure-play has more than mid-single-digit share of the $48-49 billion outsourced wallet; Sagility itself estimates its share at ~1.2%. The competitive set sits in concentric circles:

Two structural facts shape competition: (1) buyer-side concentration exceeds seller-side — the top 5 U.S. payers buy a meaningful slice of outsourced healthcare spend, and a single deal win or loss can move a mid-cap vendor's growth rate by 500 basis points; (2) scale matters less than depth — Concentrix is 15x Sagility's revenue but operates at negative GAAP margins because its mix is contact-center, not regulated clinical ops. Sagility runs the cohort's highest operating margin because the mix is right.

Regulation, Technology, and Rules of the Game

The industry exists because U.S. healthcare is the most heavily regulated services market in the developed world. Every change to CMS rules, HIPAA, state TPA licensing, or coding standards either creates work or destroys it.

The biggest framing question is GenAI. The bull case (and the case Capgemini paid US$3.3 billion for WNS to validate in October 2025) is that intelligent-operations platforms expand the BPM pie by automating end-to-end processes previously too complex to outsource. The bear case is that voice and routine claims processing — ~25% of healthcare BPM by revenue — sees per-transaction prices fall 30-50% over five years as AI displaces FTEs. Both are partially true; the regulated clinical mix is where the regulatory moat survives.

The Metrics Professionals Watch

Generic accounting ratios don't separate winners here. Seven do.

Two pseudo-KPIs to ignore: gross-margin disclosure (presented inconsistently — cost of revenue includes delivery wages for some, excludes them for others), and headcount growth on its own (without a revenue-per-FTE pairing, it's just a count). Track the mix, not the headline.

Where Sagility Ltd Fits

Sagility is the only listed pure-play U.S.-healthcare BPM vendor globally after Capgemini's acquisition of WNS in October 2025. It is small in absolute revenue (₹5,570 cr FY25 → ₹7,193 cr FY26) but holds the highest operating margin in its peer group because the mix is right and the brand is built for one buyer pool.

One sentence to carry forward: Sagility is a focus-and-margin story trading on Indian multiples while serving a US healthcare wallet that grows 5-7% per year and outsources 23-25% of its operations spend. That tension — Indian valuation framework, U.S. customer base, healthcare regulatory moat — is the arena in which every later tab plays.

What to Watch First

These seven signals tell you, faster than headline revenue prints, whether the industry backdrop is improving or deteriorating for Sagility.